Description

Retatrutide (LY3437943) is an investigational triple receptor agonist peptide currently being studied for its interaction with the GLP-1, GIP, and glucagon receptors. This multi-pathway mechanism has made Retatrutide a significant focus of ongoing metabolic and obesity-related research. Structurally engineered for extended activity, Retatrutide is being evaluated in preclinical and clinical research settings for its potential effects on energy balance, glucose regulation, and metabolic signaling pathways.

This compound is supplied strictly for laboratory and scientific research purposes only. Retatrutide is not approved for human consumption, therapeutic use, or diagnostic applications.